EdgarLookup

Exousia Bio, Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Exousia Bio, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q2 2026 Nov 30, 2025 $0 Mar 17, 2026
Q1 2026 Aug 31, 2025 $0 Nov 17, 2025
Q3 2025 Feb 28, 2025 $0 Apr 24, 2025
Q2 2026 Nov 30, 2024 $0 Mar 17, 2026
Q1 2026 Aug 31, 2024 $3.8K Nov 17, 2025
Q3 2025 Feb 29, 2024 $3.9K Apr 24, 2025
Q2 2025 Nov 30, 2023 $3.9K Jan 10, 2025
Q1 2025 Aug 31, 2023 $0 Oct 11, 2024
Q3 2024 Feb 28, 2023 $0 Apr 15, 2024
Q2 2024 Nov 30, 2022 $0 Jan 16, 2024
Q1 2024 Aug 31, 2022 $0 Oct 11, 2023

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q2 2026 Nov 30, 2025 ($19.1K) Mar 17, 2026
Q1 2026 Aug 31, 2025 ($31.8K) Nov 17, 2025
Q3 2025 Feb 28, 2025 $61.8K Apr 24, 2025
Q2 2026 Nov 30, 2024 $80.1K Mar 17, 2026
Q1 2026 Aug 31, 2024 ($3.9K) Nov 17, 2025
Q3 2025 Feb 29, 2024 ($4.8K) Apr 24, 2025
Q2 2025 Nov 30, 2023 ($3.6K) Jan 10, 2025
Q1 2025 Aug 31, 2023 ($12.2K) Oct 11, 2024
Q3 2024 Feb 28, 2023 ($8.3K) Apr 15, 2024
Q2 2024 Nov 30, 2022 ($8.4K) Jan 16, 2024
Q1 2024 Aug 31, 2022 ($13.0K) Oct 11, 2023
Q3 2023 May 31, 2022 ($937) May 8, 2023

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q2 2026 Nov 30, 2025 ($237.0K) Mar 17, 2026
Q1 2026 Aug 31, 2025 ($31.8K) Nov 17, 2025
Q2 2026 Nov 30, 2024 $7.0K Mar 17, 2026
Q1 2026 Aug 31, 2024 ($4.3K) Nov 17, 2025
Q3 2024 Feb 29, 2024 ($8.7K) Apr 15, 2024
Q2 2024 Nov 30, 2023 ($7.4K) Jan 16, 2024
Q1 2024 Aug 31, 2023 ($12.2K) Oct 11, 2023
Q3 2024 Feb 28, 2023 ($8.3K) Apr 15, 2024
Q2 2024 Nov 30, 2022 ($8.4K) Jan 16, 2024
Q1 2024 Aug 31, 2022 ($13.0K) Oct 11, 2023